Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.34 |
| ▸ | RELA | Q04206 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10513467 | 0.80 | BCKDK (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL4865586 | 0.69 | MAOA (0.34) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL10341922 | 0.67 | ATM (0.41) | NOS3NOS1NOS2MEN1MAPT | |
| SCHEMBL10341772 | 0.62 | KMT2A (0.40) | NOS3NOS1MEN1KMT2AL3MBTL1 | |
| SCHEMBL10533408 | 0.59 | ALDH1A1 (0.41) | NOS3NOS1NOS2MAPTSMN1; SMN2 | |
| SCHEMBL28586486 | 0.59 | NPC1 (0.44) | MAPTRAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL11658932 | 0.58 | NOS3 (0.45) | NOS3NOS1NOS2RAB9AKDM4E | |
| SCHEMBL21373268 | 0.57 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL21373267 | 0.57 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL20181612 | 0.57 | NOS3 (0.34) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | claimed |
| EP-0342433-A2 | Substituted dibenzothiaphenes | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | claimed |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | Neuberger, Timothy | 2008-03-20 | — | — | US | disclosed |
| US-7271187-B2 | Compositions and methods for promoting tissue regeneration | Neuberger, Tim (US) | 2007-09-18 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | NOS3 191/4885NOS1 678/4885NOS2 565/4885 |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | GAP43, DCX, BDNF | NOS3 212/4885NOS1 677/4885NOS2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.